Craig-Hallum assumed coverage of Celcuity with a Buy rating with a price target of $27, up from $25. The firm notes Celcuity provided an update on the company’s ongoing clinical trials on the Q1 call, with nothing groundbreaking. With funding through the first half of 2026, investors get to read through directly to three transformational data readouts. Craig-Hallum focuses solely on breast at the moment and thinks peak sales can be well over $2B from Geda in the 2L HR+/HER2-advanced breast setting alone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
- Celcuity Shareholders Approve Stock Plan Expansion and Elect Board
- Is CELC a Buy, Before Earnings?
- Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
- Celcuity To Present at Upcoming Needham and Stifel Investor Conferences